Earnings ·
Reports Q3 revenue of $1.12B and raises INGREZZA full-year sales guidance to $2.90-$2.93B
NBIXNeurocrine Biosciences Inc
Neurocrine Biosciences reported third-quarter 2026 total revenues of $1.12 billion, a 41% increase from the prior year period, driven by strong demand across its product portfolio. Net product sales reached $1.12 billion, with INGREZZA contributing $801 million (up 17%), CRENESSITY generating $211 million (up 115%), and VYKAT XR adding $107 million. The company raised its full-year 2026 net product sales guidance for INGREZZA to a range of $2.90 billion to $2.93 billion, up from the previous estimate of $2.825 billion to $2.875 billion. GAAP diluted earnings per share were $1.96, while non-GAAP diluted EPS came in at $3.29. The firm operates as a biopharmaceutical company focused on discovering and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders.